DOTATATE PET Imaging in Olfactory Neuroblastoma and Association with SSTR Expression

Abstract

Introduction Olfactory neuroblastoma (ONB), or esthesioneuroblastoma, is a rare neuroectodermal tumor of the nasal cavity and paranasal sinuses. Most of these tumors express somatostatin receptors (SSTRs), providing a potential target for radionuclide imaging with Ga-68 DOTATATE. However, this imaging modality has not been extensively studied in ONB.

Methods We conducted a retrospective chart review of 96 endoscopic endonasal skull base surgery cases for ONB performed at our institution between 2000 and 2021. Histo (H) scores were assigned to each tumor and normalized DOTATATE standardized uptake values (nSUVs) were measured as well.

Results Nine patients (5 males and 4 females) with ONB were ultimately included in the study. The average age of the patients was 50 years. All ONBs had a positive SSTR2 expression (H-score > 105; mean: 180). All ONBs showed DOTATATE avidity (mean nSUV for ONB: 6.7). However, there was no correlation between H-score and nSUV, with an r ² of 0.24 (p = 0.18).

Conclusion Our study shows that SSTR2 expression is found in all ONBs with associated DOTATATE avidity, which may serve as a valuable imaging modality to monitor for recurrent and metastatic disease in ONB.

Keywords

olfactory neuroblastoma - esthesioneuroblastoma - DOTATATE - SSTR2 - PET Imaging

Publikationsverlauf

Eingereicht: 16. März 2023

Angenommen: 13. Mai 2023

Accepted Manuscript online:
19. Mai 2023

Artikel online veröffentlicht:
12. Juni 2023

• References

• 1 Thompson LD. Olfactory neuroblastoma. Head Neck Pathol 2009; 3 (03) 252-259
• 2 Bell D, Hanna EY, Weber RS. et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck 2016; 38 (Suppl. 01) E2259-E2266
• 3 Hyams VJ, Batsakis JG, Michaels L. Tumors of the Upper Respiratory Tract and Ear. Washington, DC: Armed Forces Institute of Pathology; 1988
• 4 Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001; 2 (11) 683-690
• 5 Tajudeen BA, Arshi A, Suh JD. et al. Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013. J Neurol Surg B Skull Base 2015; 76 (01) 43-49
• 6 Kuan EC, Nasser HB, Carey RM. et al. A population-based analysis of nodal metastases in esthesioneuroblastomas of the sinonasal tract. Laryngoscope 2019; 129 (05) 1025-1029
• 7 Peacock JG, Harmsen WS, Link MJ. et al. Risk of delayed lymph node metastasis in clinically N0 esthesioneuroblastoma. J Neurol Surg B Skull Base 2017; 78 (01) 68-74
• 8 Fujioka T, Toriihara A, Kubota K. et al. Long-term follow-up using ¹⁸F-FDG PET/CT for postoperative olfactory neuroblastoma. Nucl Med Commun 2014; 35 (08) 857-863
• 9 Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 1993; 192 (01) 288-294
• 10 Qian ZR, Li T, Ter-Minassian M. et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas 2016; 45 (10) 1386-1393
• 11 Cracolici V, Wang EW, Gardner PA. et al. SSTR2 expression in olfactory neuroblastoma: clinical and therapeutic implications. Head Neck Pathol 2021; 15 (04) 1185-1191
• 12 Dadgar H, Norouzbeigi N, Ahmadzadehfar H, Assadi M. ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT for the management of esthesioneuroblastoma of the sphenoclival region. Clin Nucl Med 2020; 45 (08) e363-e364
• 13 Hasan OK, Ravi Kumar AS, Kong G. et al. Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma. J Nucl Med 2020; 61 (09) 1326-1330
• 14 Schneider JR, Shatzkes DR, Scharf SC. et al. Neuroradiological and neuropathological changes after 177lu-octreotate peptide receptor radionuclide therapy of refractory esthesioneuroblastoma. Oper Neurosurg (Hagerstown) 2018; 15 (06) 100-109
• 15 Ambrosini V, Kunikowska J, Baudin E. et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021; 146: 56-73
• 16 Lechner M, Takahashi Y, Turri-Zanoni M. et al. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer 2022; 162: 221-236
• 17 Ow TJ, Hanna EY, Roberts DB. et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck 2014; 36 (04) 524-530
• 18 Zhang L, Vines DC, Scollard DA. et al. Correlation of somatostatin receptor-2 expression with gallium-68-DOTA-TATE uptake in neuroblastoma xenograft models. Contrast Media Mol Imaging 2017; 2017: 9481276
• 19 Yu J, Cao F, Zhao X. et al. Correlation and comparison of somatostatin receptor type 2 immunohistochemical scoring systems with ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography imaging in gastroenteropancreatic neuroendocrine neoplasms. Neuroendocrinology 2021